文献速递生殖医学

地屈孕酮联合人绝经期促性腺激素方案在正常排卵妇女体外受精/卵胞浆内单精子注射控制性卵巢刺激联合胚胎冷冻保存中的应用

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
PubMed 文献 · Fertil Steril · 2017-07-08

前瞻性对照研究纳入250例接受体外受精/卵胞浆内单精子注射(IVF/ICSI)治疗的不孕患者,比较地屈孕酮(20 mg/d)与黄体酮(Utrogestan,100 mg/d)联合人绝经期促性腺激素(hMG)方案的內分泌特征与临床结局。两组均未出现早发促黄体生成素(LH)峰,获卵数、成熟卵数、受精卵数、可移植胚胎数及冻融胚胎移植后的临床妊娠率、早期流产率、着床率和累积妊娠率均相似。

要点

  • 地屈孕酮联合hMG方案在控制性卵巢刺激(COH)期间可稳定抑制LH,250例中无一例早发LH峰。
  • 获卵数地屈孕酮组8.22±5.46个 vs 黄体酮组8.8±5.62个,两组相似。
  • 冻融胚胎移植临床妊娠率53.04% vs 51.7%,累积妊娠率66.67% vs 69.47%,两组相似。

核心结论

  • 在正常排卵妇女的COH中,地屈孕酮在预防LH峰、胚胎特征及妊娠结局方面与黄体酮(Utrogestan)相似。

研究设计与样本

  • 前瞻性对照研究,纳入250例接受IVF/ICSI治疗的不孕患者;地屈孕酮20 mg/d或黄体酮(Utrogestan)100 mg/d自周期第3天口服至触发日,适时给予hMG 150-225 IU,优势卵泡成熟时用0.1 mg促性腺激素释放激素激动剂(GnRH agonist)触发,两组均冷冻保存可移植胚胎供后续移植。

主要发现

  • COH期间LH抑制稳定,参与者无一例发生早发LH峰。
  • 获卵数地屈孕酮组8.22±5.46个 vs 黄体酮组8.8±5.62个,两组相似。
  • 成熟卵数7.2±4.72个 vs 6.98±4.68个、受精卵数6.16±4.34个 vs 6.32±4.23个、可移植胚胎数2.96±2.22个 vs 3.4±2.54个,两组均无显著差异。
  • 临床妊娠率53.04% vs 51.7%、早期流产率8.2% vs 11.84%、着床率38.68% vs 35.71%、每名妇女累积妊娠率66.67% vs 69.47%,两组亦相似。

关键数值与推荐

  • 主要结局为获卵数;次要结局包括早发LH峰发生率、可移植胚胎数及冻融胚胎移植周期的临床妊娠结局。
  • 地屈孕酮20 mg/d或黄体酮(Utrogestan)100 mg/d口服,自周期第3天至触发日。
  • hMG 150-225 IU适时给药;优势卵泡成熟时以0.1 mg GnRH激动剂触发。
  • 临床试验注册号:ChiCTR-IOR-15007265。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate endocrine characteristics and clinical outcomes in normal ovulatory patients undergoing controlled ovarian hyperstimulation (COH) with the use of a Duphaston and hMG protocol during in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatments in combination with frozen-thawed embryo transfer (FET) compared with the characteristics and outcomes of patients undergoing an Utrogestan and hMG protocol. DESIGN: Prospective controlled study. SETTING: Tertiary care academic medical center. PATIENT(S): A total of 250 infertile patients undergoing IVF/ICSI treatments. INTERVENTION(S): Duphaston (20 mg/d) or Utrogestan (100 mg/d) was taken orally from cycle day 3 until the trigger day, with hMG (150-225 IU) administered when appropriate. When the dominant follicles reached maturity, 0.1 mg GnRH agonist was used as the trigger. Viable embryos were cryopreserved in both protocols for transfer at a later time. MAIN OUTCOME MEASURE(S): The primary outcome was the number of oocytes retrieved. Secondary outcomes included the incidence of premature LH surge, the number of viable embryos, and clinical pregnancy outcomes from FET cycles. RESULT(S): Consistent LH suppression was achieved during COH. None of the participants experienced a premature LH surge. The number of oocytes retrieved (8.22 ± 5.46 vs. 8.8 ± 5.62) was similar between the two groups. No between-group significant differences were observed in the number of mature oocytes (7.2 ± 4.72 vs. 6.98 ± 4.68), fertilized oocytes (6.16 ± 4.34 vs. 6.32 ± 4.23), and viable embryos (2.96 ± 2.22 vs. 3.4 ± 2.54). Furthermore, the clinical pregnancy rates (53.04% vs. 51.7%), early miscarriage rates (8.2% vs. 11.84%), implantation rates (38.68% vs. 35.71%), and cumulative pregnancy rates per woman (66.67% vs. 69.47%) were also similar. CONCLUSION(S): Duphaston administration during COH was similar to Utrogestan in the prevention of LH surge, embryonic characteristics, and pregnancy outcomes. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-IOR-15007265.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Zhu X, Ye H, Fu Y, et al. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertil Steril. 2017. PMID: 28697910. doi:10.1016/j.fertnstert.2017.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。